Myxomatous mitral valve disease in a Shih Tzu dog by Teoh, Y. B. & Khor, Kuan Hua
J. Vet. Malaysia (2017) 29 (1):18-22 
18 
 
Case Reports 
 
MYXOMATOUS MITRAL VALVE DISEASE IN A SHIH TZU DOG 
 
Y.B. Teoh and K.H. Khor* 
 
Faculty of Veterinary Medicine, University Putra Malaysia, UPM Serdang, Selangor, Malaysia 
 
SUMMARY 
 
An 11-year-old intact male Shih Tzu dog was referred to the University Veterinary Hospital (UVH) with history 
of coughing and laboured breathing. Auscultation revealed that the dog had a left systolic heart murmur grade V/VI at 
the base of the heart. Radiography showed findings of cardiomegaly and pulmonary oedema. Echocardiography 
findings revealed that dog has a myxomatous mitral valve disease. The mitral valve was severely thickened and 
prolapsed into the left atrium. Congestive heart failure (CHF) was treated with an angiotensin converting enzyme 
(ACE) inhibitor and diuretic. An anti-mucolytic agent was prescribed as a symptomatic treatmentfor the coughing that 
could be due to mild bronchitis. Dog did not response well with treatment as the frequency of cough was not reduced 
and the duration was longer each time. Pimobendan was then added on to the initial treatment and there was a 
tremendous improvement seen from the patient after that. Episodes of productive cough were noticed greatly reduced 
and dog was much more active at home post two weeks of ACE inhibitor, diuretic and dual-acting inodilator. We 
successfully maintained the dog with minimal coughing episodes. However, the prognosis is moderate to poor in this 
case due to possibilities of refraction towards medications.  
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INTRODUCTION 
 
Myxomatous mitral valve degeneration (MMVD) is 
the most common acquired type of canine heart disease. It 
is refers to as a non-infectious degeneration of heart 
valves commonly seen in older dogs. MMVD is a 
manifestation of a process that can affect all heart valves 
but usually it is detected in the mitral valve. Mitral valves 
are the most commonly reported valves affected in canine 
heart disease patient and followed by the tricuspid valves 
(Kittleson and Kienle, 1998; Vörös et al., 2015). 
MMVD can also be termed differently in various 
literatures such as chronic valve disease, degenerative 
valve disease and mitral valve endocardiosis (Petric, 
2015). The disease is sequelae of a chronic degeneration 
of the mitral valves, for which the valves become 
thickerwith irregular/nodular surface. The structural 
changes impede the valvular function to form a tight seal 
between the atrium and ventricle during cardiac 
contraction (Kittleson and Kienle; 1998). When mitral 
valves failed to close tightly, the blood flowing to the 
ventricle post atrial contraction will back flow to the left 
atrium, causing a regurgitation (MacGregor, 2014). 
Chronic regurgitation would induce enlargement of both 
the left atrium and ventricles. The compensatory 
mechanism of the heart due to increased leaked volume 
over time may cause pressure to build up in the left 
atrium, transmitting an upstream to the lungs leading to 
pulmonary oedema, which is a sign of congestive heart 
failure (CHF) (MacGregor, 2014). MMVD affects 
primarily small breed dogs later in life but can affect 
larger breed dogs. Breeds reported to be predisposed to 
MMVD includes small mixed breed dogs such as 
Cavalier  
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King Charles Spaniels, Cocker Spaniels, Pekingese, 
Dachshunds and also Shih-Tzu (Atkins et al., 2009). 
 
CASE REVIEW 
 
An 11-year-old intact male Shih Tzu dog was 
referred to University Veterinary Hospital, Faculty of 
Veterinary Medicine (UVH-FPV) with history of 
coughing and laboured breathing. The dog had severe 
increased coughing and labour breathing for 3 months 
prior to presentation at UVH. The dog was treated with 
furosemide and benazepril for 7 days by the private 
veterinarian and the coughing episodes reduced. 
However, three days prior to presentation at UVH, the 
dog had relapsed episodes of coughing and laboured 
breathing. Again, the dog was prescribed with the same 
drugs and was then referred to the UVH for 
cardiovascular diagnostic workout. 
Upon physical examination, the dog was quiet, alert 
and responsive. Temperature and heart rate were within 
normal limits with a body condition score of 2.5 out of 
5.0. Vaccination and deworming status were up-to-date. 
Upon observation, the dog was panting heavily. Dog has 
severe halitosis due to gingivitis and severe accumulation 
of tartar built up on the surface of the bilateral molars and 
pre-molars. Heart auscultation revealed that patient had 
systolic heart murmur grade V/VI with maximum point of 
intensity at the left heart base. Further auscultation 
revealed crackled lung sounds and a productive cough 
was triggered post tracheal pinch. Thoracic radiograph of 
the right lateral view (Figure 1A) and dorso-ventral view 
(Figure 1B) revealed findings of cardiomegaly with the 
Vertebral Heart Score (VHS) of 11 with tracheal elevated 
dorsally, with the differential diagnosis of chronic 
degenerative valvular disease, MMVD, triscuspid 
endocardiosis and dilated cardiomyopathy. There was an 
increased opacity of the lung parenchyma from hilar to 
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Figure 1A. (On the left) In the right lateral view of the chest radiograph, cardiomegaly was diagnosed with the 
presence of increased in sternal contact, elevation of trachea dorsally and vertebral heart score (VHS) of 13. 
Pulmonary oedema was diagnosed with the presence of increase in radio-opaciy of caudal lung lobe with mixed 
interstitial pattern. Figure 1B. (On the right) In the dorso-ventral view of the chest radiograph, cardiomegaly 
was noted with the globoid heart shape and reduced space between the right and left heart outline to the 
thoracic ribs. There was a bilateral increased in radio-opaciy of caudal lung lobe with mixed interstitial pattern 
suggestive of pulmonary oedema.  
 
Figure 2. (On the left) Based on echocardiography of the right parasternal long axis view of  the heart’s image, 
there was a severe thickening of mitral valves. Upon contraction of the left ventricle, both the anterior and 
posterior leaflets were closed inadequately and have signs of mitral valve prolapse. (On the right) In the right 
parasternal long axis view with color flow Doppler of the heart in echocardiography, there were mixing of color 
seen in both left atrium and left ventricle which indicate a disrupton of the blood flow from left ventricle in to 
the left atrium. 
 
Table 1. Parameters of the left ventricle (LV) were collected from the M-mode of right parasternal short axis 
view at the papillary muscle level 
Parameter Average result Reference range Interpretation 
LVID at diastole 47.8 29.0 Dilated ventricular lumen 
LVID at systole 24.6 19.0 
LVPW at diastole 8.6 7.0 Thickened ventricular wall 
LVPW at systole 11.3 10.0 
La:Ao ratio 2.27 1.60 Increase atrium size 
 
LVID, Left ventricular wall internal dimension; LVPW, Left ventricular posterior/free wall thickness; La, Left atrium; Ao, Aorta 
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perihilar region of the dorsal lung field with alveolar 
pattern suggestive of pulmonary oedema. For 
confirmatory diagnosis of the heart condition, 
echocardiography was performed. The right parasternal 
long axis view of the heart image showed thickening of 
mitral valves, reduced in the proximity of the mitral 
valvular leaflets upon closure with sign of mitral valve 
prolapsed into the left atrium (Figure 2).  
On the same view, the presence regurgitation of 
blood flow in both, the left atrium (LA) and left ventricle 
(LV) was evident using a color flow Doppler (Figure 2). 
Right parasternal short axis view at point the mitral valve 
level revealed similar thickening apperance of both, the 
anterior and the posterior leaflets of the mitral valve. 
Measurement of the LV were collected from the M-mode 
of right parasternal short axis view at the papillary muscle 
level. The abnormal findings were increased of the left 
ventricular internal dimension (LVID), increased of the 
left ventricular free wall thickness (LVPW) as well as the 
left atrium to aorta ratio (La:Ao) (Table1). Final diagnosis 
for cardiomegaly in this case was MMVD. 
Dog was treated with benazepril hydrochloride 
(Fortekor®, Novartis Animal Health, Switzerland) at 0.5 
mg/kg, once a day orally for 30 days. Benazepril 
hydrochloride is an angiotersin converting enzyme (ACE) 
inhibitor to suppress to renin angiontensin aldosterone 
system (RAAS) of the juxtoglomerular junction to prevent 
rentention of fluid to control the heart murmur. Pulmonary 
oedema was treated with furosemide (Rasitol 40mg, 
Y.S.P. Industries (M) Sdn. Bhd., Malaysia) at 2 mg/kg 
orally thrice a day for 5 days and then tapered to twice a 
day for 5 days and then further reduced to once a day for 5 
days. Frusemide is a loop diuretic which helps to reduce 
fluid and salt retention in the body by preventing 
antidiuretic hormone (ADH) action in the Loop of Henle. 
A symptomatic treatment of the coughing was prescribed 
with bromhexine hydrochloride (Bislan 8 mg, Y.S.P. 
Industries (M) Sdn. Bhd., Malaysia) at 1 mg/kg twice a 
day for 7 days). It is a mucolytic agent which aids in 
breaking down mucous in the respiratory tract. After 2 
weeks of treatment with furosemide and benazepril 
hydrochloride, the frequency and the duration of the dog’s 
cough did not improve over time. Hence, an additonal 
medication of pimobendan (Vetmedin®Chew 5 mg, 
Boehringer Ingelheim, United Kingdon), a dual-acting 
inodilator was prescribed at 0.5 mg/kg (dose split to half 
morning and half at night) for 30 days in order to promote 
cardiac contractility and it’s vasodilation effect. At the 
same time, dog was also maintained on both benazepril 
hydrochloride and frusemide during the 30 days 
treatment. 
After 4 weeks of pimobendan oral administration 
added to the treatment regime, the dog was reported to be 
very active at home with no signs of exercise intolerance. 
Episode of cough was only heard during excitement. 
Echocardiography was repeated and revealed that the 
parameters of the left side of the heart improved with LV 
wall thickness, LV lumen size and La:Ao ratio reduced. In 
the subsequent revisits at 10 weeks and 14 weeks after 
initial treatment, the dog was reported to coughed once at 
night. The treatment was continue as a life long regime to 
control CHF. 
DISCUSSION 
 
MMVD is the most common acquired type of heart 
disease in older dogs (MacGregor, 2014), primarily 
affecting the small breed dogs later at older age. However, 
this can affect larger breed dogs as well. Cavalier King 
Charles Spaniel being the most prominent breed described 
and diagnosed with MMVD (Beardow et al., 1993, 
Kittleson and Kienle, 1998). Studies have shown that 
genetic factors play a large role in causing MMVD, due to 
the polygenetic inheritance especially in Cavalier King 
Charles Spaniel (CKCS) and Daschund dogs. Multiple 
genes which influence this trait that causes MMVD 
require a reach of certain threshold, for which male dogs 
have a lower threshold as compared to female; 
predisposing them to MMVD clinical manifestation at a 
younger age (Häggström et al., 2004). Although studies 
have not been conducted extensively in the Shih Tzu dog, 
this breed has been frequently reported and correlations 
with the genetic factor was suggested (Petric, 2014). 
Older, small breed dogs of less than 20 kg have been 
reported to be more commonly affected with MMVD, but 
itis not limited to small breed dogs only (Margiocco, 
2010). Large breed dogs may be affected by MMVD but 
disease progression was reported to be much rapid as 
compared to small breed dogs (Atkins et al., 2009). 
Hence, dog owners need to be awared and educated about 
the possible risk upon adoption of breeds mentioned 
above. Awareness and knowledge of canine heart disease 
would allowed immediate attention when clinical signs 
manifest. 
MMVD is a manifestation of a process that can 
affect all heart valves but usually it is detected in the 
mitral valve. In a normal condition, the LA is the chamber 
that oxygenated blood flows into after passing through the 
lungs. Blood then passes through the mitral valve into the 
LV and gets pumped out into the body circulation. The 
mitral valve closes when the LV contracts and thus 
preventing blood from flowing back into the LA. An 
unaffected mitral valve is thin and supple, anchored in 
place by strands of tissue called the chordae tendinae. The 
pathophysiology of MMVD have been well described in 
dogs. MMVD is a process that occurs when the mitral 
valves becomes thickened. Grossly, the mitral valvular 
leaftlets appears thicker with nodular pattern at the edge 
of  the valvular leaftles. Histologically, the thickening of 
the spongiosa and the degeneration of  fibrosa layer 
remain as the classical feature of MMVD (Maxie, 2015).  
As the degeneration of the mitral valvular leftlet 
progresses, the abnormal structure will then prevent 
effective coaptation (closing) of the valves and hence 
resulting in regurgitation of blood back flowed (leak) into 
the LA, known as mitral regurgitation. The regurgation 
leads to an increase in cardiac work, remodeling of 
ventricle and finally ventricular dysfunction (Atkins et al., 
2009). Clinically, cardiac remodelling will cause 
ventricular dilatation as well as LV wall hypertrophy. 
Over time, LA will be dilated due to the progressive 
backflow of the blood which haveworsened and often 
dogs will not show signs of CHF if the atrium still can 
contain the regurgitated blood. The exact time course for 
the clinical sign of CHF varies from patient to patient. The 
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increasing volume of the leak along with long-term 
compensatory mechanisms eventually leads to an increase 
in the pressure within the atrium. The increase pressure in 
the LA is transmitted upstream to the lungs leading to 
fluid exuding from the capillaries into the alveoli of the 
lungs, causing pulmonary oedema (Rozanski et al., 2012). 
Besides that, the increase of pressure in LA can also 
happen suddenly if the corda tendinae ruptures and 
produces a partially unanchored mitral valve, known as 
mitral valve prolapse (Jeresaty et al., 1985). In this case, 
we suspected that the corda tendinae was weaken hence 
the mitral slightly prolapsed into the LA upon closure. 
Symptoms of CHF generally do not appear for 3 to 4 
years after the diagnosis of heart disease. Often the first 
outward sign of worsening MMVD is a cough, which was 
the primary complaint for this patient. Coughs often 
occurred due to two reasons. In the advanced stage of 
MMVD, general cardiac enlargement or the increment in 
LA chamber size may cause the trachea to be elevated 
dorsally. It was speculated to cause a degree of airway 
collapse in the trachea, or even contributing to concurrent 
bronchitis due to severe injury to the lungs and brochi 
from the severe coughing (Rush,2002). Cough in patients 
with MMVD due to the congestion in the lungs (signs of 
CHF) requires immediate medical attention. A recent 
study has documented that rising breathing rates during 
sleep are likely to be indicative of worsening heart 
disease. As seen in this case, crackles were heard upon 
auscultation and findings were consistent with the chest 
radiograph with the evidence of pulmonary oedema 
(Rush, 2002). Radiograph of the the thoracic often 
provides information about the severity of the disease by 
looking at heart size and are often the definitive means in 
diagnosing CHF (Atkins et al., 2009).  
Systolic murmur with a maximum point of intensity 
at the left heart base was characteristics of MMVD during 
cardiac auscultation. A diagnosis of MMVD using 
echocardiography provides the definitive ante mortem 
diagnosis and distinguishes MMVD from other murmurs 
of cardiac causes. The leak in the mitral valve can be 
detected by colour flow Doppler echocardiography.  
Severity or the stages of heart condition can be made 
based on the Classification of Chronic Degenerative 
Valvular Disease (CDVD) (Atkins et al., 2009) (Table 2). 
The patient in this case was classify as Stage C in which 
the dog showed clinical sign of CHF with evidence of 
abnormal findings in the radiograph and 
echocardiography. Some patients have been reported to 
have life-threatening clinical signs at Stage C but this dog 
was only presented for excessive coughing and lethargy. 
Chronic (or home-based) therapy for Stage C patients was 
recommended based on the consensus which includes 
prescription of furosemide (1–2 mg /kg q12 hr to 4–6 
mg/kg q8 hr orally), ACE-inhibitor (dose depends of the 
drug used), pimobendan (0.25–0.30 mg/kg q12 hr). 
Furosemide is a very potent loop diuretic and it acts on the 
kidneys to help reduce lung congestion by reducing fluid 
retention. Pimobendan helps the heart work more 
effectively and has been shown to improve survival in 
MMVD patients (Boswood, 2016). ACE-inhibitors and 
spironolactone block deleterious compensatory 
mechanisms that occur with severe heart disease and have 
been shown to prolong survival as well (Lefebvre, 2007). 
Other medications that are sometimes used in treatment of 
CHF include hydrochlorothiazide, amlodipine and 
torsemide (de Madron, 2011). Often the onset of 
congestive heart failure is sudden and may require 
hospitalisation. When patients are hospitalised, patients 
generally receive supplemental oxygen and intravenous 
furosemide therapy. This therapy usually allows patients 
to get past the initial crisis stage and most patients are able 
to survive the crisis and resume normal life with the 
assistance of medication. Dietary modification including 
sodium restriction is useful at this stage to prevent the 
recurrent of pulmonary oedema (Atkins et al., 2009).  
Cardiac cachexia may be of concern, hence 
maintenance of adequate calorie intake is required. 
Controlled salt intake is extremely crucial in order to 
control the clinical signs of CHF. The consensus have 
suggested that modest restriction of sodium intake in all 
dietary sources with avoidance of  processed or salted 
food if possible (Atkins et al.,2009). Hence, the patient 
was maintained with the Royal Canin Cardiac diet which 
provides vascular support, early renal support, electrolyte 
balance and cardiac support. Goals in treatment and diet 
control in MMVD patients are to prolong lifespan and 
improve quality of life with less stressful episodes as 
result of clinical signs.  
 
Table 2. The four stages for classification of chronic 
degenrative valvular disease (CDVD) (Atkins et al., 
2009) 
 
Generally, it is recommended to review the heart 
condition every 6-12 months during the pre-clinical phase 
Stage Definition 
Stage A Dogs at risk for CDVD but have no 
identifiable cardiac structure disorders 
(i.e. Cavalier King Charles Spaniel, 
Dachshunds) 
Stage B1 Dogs with CDVD, that have never 
develpoed clinical signs and do not have 
radiographis or echocardiographic 
evidence of cardiac remodelling 
Stage B2 Dogs with CDVD, that have never 
developed clinical signs have  
radiographic or echocardiographic 
evidence of cardiac remodelling (i.e. left-
sided heart enlargement) 
Stage C Dogs with CDVD and past or current 
clinical signs of heart failure associated 
with structural heart remodelling. 
• Dogs presenting heart failure for 
the first time may present severe 
clinical signs andmay require 
hospitalisation 
• These dogs needs treatment to 
stay free from symptoms of hear 
failure 
Stage D Dogs with end-stage CDVD and heart 
failure that is refractory to standard 
therapy (i.e. furosemide, ACEIs, 
pimobendan +/- spironolactone) 
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of MMVD to monitor progression of the disease. Once 
clinical signs develop, rechecks may occur more 
frequently - every 3 to 4 months or as needed depending 
on patient’s condition (Olson, 2014). Rechecks might 
involve blood tests to monitor kidney function and 
electrolyte levels as these can be negatively affected by 
the medications used to treat CHF. Radiograph of the 
chest are utilised to assess the recurrence of CHF and 
echocardiograms to monitor heart size and blood flow 
related to conditions in the heart. Recently, the cardiac 
biomarker N-terminal pro b-type natriuretic peptide (Nt-
proBNP) has been developed as an aid for the diagnosis 
and monitoring of disease progression in MMVD. It is a 
species specific cardiac biomarker which have been 
developed into instant test kits to detect elevated serum 
NT-proBNP levels, helping clinicians to determine the 
severity of the disease. As the cardiac muscles stretch 
during a pressure overload, the peptides will be released, 
hence being detected by the test kits (Wolf et al., 2013). 
The prognosis for newly diagnosed MMVD varies 
widely. While the average time from when a murmur is 
first heard until CHF is present is approximately four 
years, the speed of progression of the disease is difficult to 
predict for individual patients. Once a patient has 
developed congestive heart failure, the average survival 
span is 12-14 months, although this can vary as well 
(Gompf, 2011). This dog survived 344 days and had 
enjoyed an extended days of good quality of life. The 
most frequent cause of death for MMVD patients in 
congestive heart failure is euthanasia due to either 
inability to control the signs of congestion such as ascites, 
coughing, dyspnea, anorexia or wieghtloss regardless of 
medication dose given or inability of the patient to tolerate 
the amount of medication needed to control congestion 
(Mallery, 1999). 
 
CONCLUSION 
 
MMVD is a manageable disease with diligent 
medication and dietary monitoring, but is incurable due to 
the irreversible effect of the chronic degenration of the 
mitral valves. Owners need to be aware that it would be a 
life long commitment to maintain the quality of life of the 
dog, with full compliance to the treatment regime for the 
best effects on reaching the treatment goals; prolonging 
lifespan and improving quality of life by controlling 
clinical signs of CHF.  
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